We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 641

No Duty to Consult Indigenous Groups on Legislation - Mikisew Cree First Nation v. Canada (Governor General in Council)
  • McCarthy Tétrault LLP
  • Canada
  • October 18 2018

The Supreme Court of Canada (SCC, or the Court) has ruled that there is no duty to consult Indigenous groups at any stage of the law-making process


Hilton Worldwide Holding LLP v. Miller Thomson (2018 FC 895)
  • Marks & Clerk
  • Canada
  • October 12 2018

A recent decision of the Federal Court has confirmed that use of a trademark in Canada with “hotel services” does not require a “bricks-and-mortar”


Online Reputation subject of Privacy Commissioner reference to Federal Court
  • Osler Hoskin & Harcourt LLP
  • Canada
  • October 11 2018

The Office of the Privacy Commissioner of Canada (OPC) has announced that it is asking the Federal Court to determine whether Google is subject to


Prohibition denied for Ranbaxy's bupropion extended-release tablets
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • October 1 2018

On August 20, 2018, the Federal Court dismissed Valeant's PMNOC application regarding Ranbaxy's bupropion extended-release tablets (Valeant's


Amended PMNOC Regulations: First Anniversary Update
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • September 28 2018

As previously reported, the amended Patented Medicines (Notice of Compliance) Regulations (“Regulations”) came into force on September 21, 2017


Federal Court of Appeal dismisses Apotex’s appeal in judicial review of Health Canada decision seeking further information from facilities in India
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • August 29 2018

As previously reported, the Federal Court dismissed Apotex's application for judicial review of the decision of the Therapeutic Products Directorate


Federal Court dismisses first motion for early dismissal under amended PMNOC Regulations
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • August 27 2018

In public reasons released on July 30, 2018, the Federal Court dismissed the first motion for summary dismissal brought under section 6.08 of the


Eli Lilly’s EFFIENT combination use patent found obvious
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • August 27 2018

On July 13, 2018, the Federal Court dismissed Eli Lilly’s application for a prohibition order, finding that Apotex’s allegation of obviousness of


Teva succeeds in section 8 bortezomib action; infringement counterclaim dismissed
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • August 27 2018

On July 18, 2018, Justice Locke of the Federal Court granted Teva’s claim for compensation under section 8 of the Patented Medicines (Notice of


A Lesson on When to Strike: Case Comment on Badawy v 1038482 Alberta Ltd et al., 2018 FC 807
  • McCarthy Tétrault LLP
  • Canada
  • August 3 2018

In a Federal Court decision released on July 31, 2018, Badawy v 1038482 Alberta Ltd et al, a claim for infringement of intellectual property was